<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010295</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG27</org_study_id>
    <secondary_id>EudraCT number 2006-005795-41</secondary_id>
    <nct_id>NCT01010295</nct_id>
  </id_info>
  <brief_title>A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae</brief_title>
  <acronym>IELSG27</acronym>
  <official_title>A Clinico-pathological Phase II Study With Translational Elements to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae With Particular Reference to Chlamydia Species and the Effects of MALT Lymphoma Treatment With Tetracycline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexae (MLOA)
      will be eligible for treatment with doxycycline (part A: clinico-pathological study);
      patients with other types of ocular lymphoma, inflammatory lesions or those
      ineligible/unwilling for treatment with doxycycline can participate in the only pathologic
      study (part B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with suspected lymphoma of the ocular adnexae will undergo a diagnostic biopsy in
      the usual way. If lymphoma is confirmed the patient will undergo a full staging evaluation
      and entry into either part A or B of the study will then be considered as follows:

        -  clinico-pathological (part A) for patients with MALT lymphoma of the ocular adnexae
           (MLOA) and eligible for treatment with Doxycycline 100 mg twice daily for 3 weeks ; or

        -  pathology only (part B) for patients with other types of ocular lymphoma, inflammatory
           lesions or those ineligible/unwilling for treatment with doxycycline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rates</measure>
    <time_frame>at 6 weeks, 12 weeks, 12 months and 24 months from start of doxycycline</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>doxycycline 100 mg twice daily for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline (tetracycline)</intervention_name>
    <description>doxycycline 100 mg twice daily for 3 weeks</description>
    <arm_group_label>doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or over

          2. Histologically confirmed marginal zone B-cell lymphoma of MALT-type

          3. Lymphoma localised to the ocular adnexae (conjunctiva, lacrimal gland, orbit soft
             tissue, clinical stage IEA) following a CT scan of neck, thorax, abdomen and pelvis,
             bone marrow aspirate/trephine, full blood count and biochemical profile

          4. No previous treatment, excepting RT for localised lymphoma of the contralateral eye

          5. At least one measurable lesion

          6. No systemic antibiotic therapy in the last three months

          7. No other malignancy in the previous 5 years apart from appropriately treated basal
             cell carcinoma of the skin or carcinoma in situ of the cervix

          8. In women with reproductive potential a willingness to use contraception from entry
             into the study for a period of 3 months

          9. Written informed consent

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Known allergy to tetracycline

          3. Patients unwilling to comply with the requirements of follow-up as defined by this
             protocol

          4. Myasthenia gravis (tetracycline can exacerbate muscle weakness)

          5. Systemic lupus erythematous (tetracycline can exacerbate the condition)

          6. Patients with large or rapidly enlarging tumours requiring immediate radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andr√©s JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>International Extranodal Lymphoma Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital del Salvador</name>
      <address>
        <city>Providencia, Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele, Department of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Bianchi-Melacrino-Morelli, Divisione di Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IOSI</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NHL of the ocular adnexae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

